Prof Lawrence Steinman, MD. received his BA (physics) from Dartmouth in 1968 and his MD from Harvard (1973). He had a fellowship in chemical immunology at the Weizmann Institute (1974-1977) and was an intern and resident at Stanford University Medical School. Steinman served as the Chair of the Interdepartmental Program in Immunology at Stanford University from 2003-2011. He completed his Honorary PhD at the Hasselt University in 2008. Prof Lawrence Steinman currently is the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University. He is a member of the National Academy of Medicine, and the National Academy of Sciences, USA. Prof Lawrence Steinman also founded the Steinman Laboratory in Stanford University, which is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. In this laboratory he has developed several new therapies for autoimmunity, including some in Phase 2 clinical trials in multiple sclerosis and type 1 diabetes mellitus, as well as one approved drug, natalizumab. He has also developed microarray technology for detecting autoantibodies to myelin proteins and lipids. His laboratory team employs a diverse range of molecular and cellular approaches to devise new medications for demyelinating diseases, and to help predict which current medications will work at various stages of these diseases.
Prof Lawrence Steinman received the Frederic Sasse Award from the Free University of Berlin in 1994, the John Dystel Prize in 2004 from the National MS Society in the US, the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011 from the International Federation of MS Societies, and the Cerami Prize for Translational Research in 2015.
Further achievements Prof Lawrence Steinman has been given include the Anthony Cerami Award in Translational Medicine by the Feinstein Institute of Molecular Medicine in 2015. The US congress awarded Prof Lawrence Steinman the Sen. Jacob Javits Award across 1988 and 2002. Steinman has been involved in two prominent exits: Steinman served on the Board of Directors of Centocor which was sold to Johnson and Johnson for $4.9B USD in 1998. He founded Neurocrine Biosciences (NASDAQ:NBIX Market Cap $6.21B USD) in 1992 and served on their Board of Directors. Neurocrine Biosciences (NASDAQ: NBIX) had an IPO in 1997. Neurocrine Biosciences (NASDAQ:NBIX) is a San Diego, CA based biotechnology company that focuses on neurologic, psychiatric and endocrine related disorders, currently it has three late-stage clinical programs, which is a novel achievement based on Prof Steinman’s initial guidance. It currently has a market cap on the NASDAQ of $9.72B USD.
He has founded three other companies, Tolerion, Transparency Life Sciences and Atreca. Steinman heads the Scientific Advisory Board at Transparency Life Sciences. Prof Lawrence Steinman also serves on the Board of Directors at Atreca and Tolerion.
DR. JONATHAN B ROTHBARD
Chief Executive Officer, Chief Scientific Officer and Co-Founder
Dr Jonathan Rothbard, PhD received his BA from Hamilton College (1973) and his PhD from Columbia with Ronald Breslow (1977). His post-doctoral fellowship was with Gerald Edelman at The Rockefeller University after which he was with Gary Schoolnik at Stanford University Medical School where he published the first of 26 manuscripts with Lawrence Steinman in 1986. Subsequently, he was head of the Molecular Immunology Laboratory at the Imperial Cancer Research Fund in London, where he first collaborated with Prof Sir Marc Feldman (1990).
He left academia to help establish ImmuLogic in Palo Alto, and founding Amylin in San Diego. Amylin, which he founded in 1987, was a pharmaceuticals company engaged in the discovery, development and commercialization of drugs relating to diseases including obesity and diabetes. The success of Amylin led to another appointment at Stanford for Dr Rothbard, followed by the founding of CellGate. Leaving CellGate, he returned to an appointment at Stanford, first in the department of chemistry, then rheumatology, and currently in neurology. Amylin was sold to Bristol-Myers Squibb (NYSE:BMY Market Cap $82.49B USD) in 2012 for $5.4 Billion USD.
PROF. SIR MARC FELDMANN
Director, Co-Founder and Chairman of the Advisory Board
Prof Sir Marc Feldmann, AC FAA FRS FRCP FRCPath FMedSci is a preeminent immunologist, and a Prof at the University of Oxford. After graduating with an MBBS degree from the University of Melbourne in 1967, he earned a Ph.D. in Immunology at the Walter and Eliza Hall Institute of Medical Research in 1972 with Sir Gustav Nossal. Prof Sir Marc Feldmann undertook postdoctoral research (1972) at the Imperial Cancer Research Fund’s Tumour Immunology Unit with Prof Avrion Mitchison, which led to the generation (1983) of a new hypothesis for the mechanism of autoimmunity. Testing this idea led him to leave ICRF and move to the Charing Cross Sunley Research Centre in 1985, which merged with the Kennedy Institute of Rheumatology. This then joined with the Faculty of Medicine at Imperial College in 2000. In August 2011, the Kennedy Institute of Rheumatology transferred to the University of Oxford. In 1983, he published a new hypothesis for the mechanism of induction of autoimmune diseases, highlighting the role of cytokines. Cytokines are potent signalling proteins, local hormones, which drive important processes like inflammation, immunity and cell growth. In collaboration with Ravinder N. Maini at the Kennedy Institute of Rheumatology they demonstrated that diseased joints have excessive Tumour Necrosis Factor Alpha and with the help of Dr F Brennan, TNF was defined as a therapeutic target for RA since blocking it in cultures of human arthritic joint tissue or in arthritic mice had profound beneficial effects.
Prof Sir Marc Feldmann’s research has led to his recognition as a pioneer in immunology. He is Fellow of the Royal College of Physicians and of the Royal College of Pathologists. He was elected a Fellow of multiple national Academies, the Academy of Medical Sciences and the Royal Society in London, the Australian Academy of Science, and he is a Foreign Member of the National Academy of Sciences, USA. He was knighted in the 2010 Queen’s Birthday Honour for his outstanding services to medicine.
Along with Dr. Maini, Dr. Feldman was awarded the Crafoord Prize “for identification of TNF blockade as an effective therapeutic principle in rheumatoid arthritis, In 2003, the two were awarded the Albert Lasker Award for Clinical Medical Research for “discovery of anti-TNF therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases”. In 2004, the Cameron Prize for Therapeutics of University of Edinburgh. In 2007, Feldmann was awarded The European Patent Offices “European Inventor of the Year” in the Lifetime Achievement Category, the first award made in medicine. In 2008 he was awarded the Dr. Paul Janssen Award for Biomedical Research together with Maini. He was awarded the John Curtin Medal of the Australian National University in 2007. Feldmann and Maini were awarded the Ernst Schering Prize in Germany in 2010, and the Canada Gairdner International Award in 2014. Prof Sir Marc Feldmann is an Emeritus Prof at the Kennedy Institute of Rheumatology, Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences in the University of Oxford. Centocor licensed Feldmann and Maini’s key patent, and then developed Infliximab, ultimately branded as Remicade. Remicade was the main driver of the $4.9B USD acquisition of Centocor by Johnson and Johnson and is the 4th highest selling drug in the word, reaching over $8 Billion USD in sales in 2018. Prof Sir Marc Feldmann is an expert in the development of anti-inflammatory therapeutics. Anti-TNF therapeutics which they pioneered are since 2012 the most profitable Pharmaceutical drug class with sales in 2016 that exceeded $36B USD.
Prof Sir Marc Feldmann has authored over 600 published papers reflecting an overarching commitment to both the cellular aspects of inflammatory autoimmune biology messenger molecules, cytokines and therapeutic applications.
Chief Operating Officer and Director
Lawrence Pemble has comprehensive experience in successfully creating, financing and developing biotechnology businesses. He has led companies and individual projects from the development and discovery phases through to financing and further clinical development.
A strong technical, entrepreneurial and corporate finance background, formatively developed within the Private Equity space where Lawrence was a Principal of a Life Science Private Equity Firm and latterly as COO of Publicly Traded and Private Biotechnology and Medical Technology companies. Lawrence currently serves as COO of Hemogenyx Pharmaceuticals PLC, an oncology biotech company listed on the London Stock Exchange.
Lawrence has lead numerous financing rounds, M&A activities, IPOs and has held executive roles, up to and including CEO, for start-up and private equity backed ventures, both in private and public capacities.
Lawrence has a sharp understanding and interest in the regulatory and scientific processes and procedures involved in effectively and efficiently moving young biotechnology companies from their roots to the clinical phases.
Mr. DeMare is the President and principal of Chase Management Ltd., a private company providing a broad range of administrative, management and financial services to private and public companies involved in mineral exploration and development, gold and silver production, oil and gas exploration and production and venture capital.
For over 20 years, Mr. DeMare has assisted numerous companies in making the transition from the private to public stage and arranging and participating in equity and debt financing. Prior thereto, Mr. DeMare was employed as a General Practice Manager with Coopers & Lybrand, Chartered Accountants.
Mr. DeMare is currently a director and/or officer of a number of public companies listed on the Toronto Stock Exchange and the TSX Venture Exchange, including Advantage Lithium (TSX.V: AAL, Market Cap: $150M CDN) and Tinka resources Resources (TSX.V: TK, Market Cap of $107M CDN). Mr. Demare was also CFO of American Oil & Gas, which was sold to Hess Corporation in an all stock deal worth $445M USD.